Abstract
Risperidone (RIS) has the highest propensity to elevate plasma prolactin (PRL) levels. While the active metabolite 9-hydroxy-risperidone (9-OH-RIS) plays a predominant role in the efficacy and side effects of RIS, the mechanistic details are still poorly understood. The present study evaluated the gender differences in the relationship between plasma levels of RIS or 9-OH-RIS and PRL. Twenty-one male and 19 female subjects treated with RIS were enrolled in the present series. All patients had been receiving RIS for at least 4 weeks at an average dosage of 4.7 mg/day. Plasma RIS, 9-OH-RIS and PRL levels were measured. In the male patients, there was no correlation between the RIS dosage and plasma PRL levels, between plasma RIS levels and PRL levels, or between the plasma 9-OH-RIS levels and PRL levels. In the female patients, there was a significant positive correlation between the plasma 9-OH-RIS levels and PRL levels (rs=0.456, p=0.049). There was a trend toward a significant positive correlation between the RIS dosage and plasma PRL levels. There was no correlation between the plasma RIS levels and PRL levels. 9-OH-RIS is considered to play a more important role in PRL elevation than RIS, and a gender difference exists in th...Continue Reading
References
Dec 1, 1973·The Journal of Clinical Endocrinology and Metabolism·M T Buckman, G T Peake
Feb 6, 1999·Journal of Clinical Psychopharmacology·D L KleinbergM Brecher
Mar 23, 2002·Journal of Clinical Psychopharmacology·Shubulade SmithVeronica O'Keane
Mar 26, 2003·Psychoneuroendocrinology·Bruce J KinonUriel M Halbreich
Jan 28, 2004·The Journal of Clinical Psychiatry·Jan VolavkaJeffrey A Lieberman
Oct 1, 2004·Drugs·Peter M Haddad, Angelika Wieck
May 3, 2005·The American Journal of Psychiatry·Rikus KnegteringRobert J van den Bosch
Feb 10, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Bun-Hee Lee, Yong-Ku Kim
Jul 11, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Kazushi SawamuraToshiyuki Someya
Nov 10, 2006·Human Psychopharmacology·Kristina I Melkersson
Jun 15, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Norio Yasui-FurukoriSunao Kaneko
Aug 24, 2007·Journal of Psychopharmacology·Lei WangLin He
Aug 16, 2008·Journal of Psychopharmacology·Peter Fitzgerald, Timothy G Dinan
Jun 18, 2009·Therapeutic Drug Monitoring·Alfonso M LostiaRoberto Tatarelli
Feb 23, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Norio Yasui-FurukoriSunao Kaneko
Citations
Dec 25, 2015·Psychiatry Research·Sri Mahavir AgarwalBangalore N Gangadhar
Jul 2, 2015·Clinical Pharmacokinetics·Frederik VandenbergheChin B Eap
Dec 7, 2011·Human Psychopharmacology·Yutaro SuzukiToshiyuki Someya
Jun 30, 2012·Human Psychopharmacology·Yutaro SuzukiToshiyuki Someya
Feb 5, 2013·Schizophrenia Research·Yutaro SuzukiToshiyuki Someya
Feb 18, 2016·Basic & Clinical Pharmacology & Toxicology·Nattawat NgamsamutChonlaphat Sukasem
Apr 24, 2013·Journal of Clinical Psychopharmacology·Yutaro SuzukiToshiyuki Someya
May 7, 2020·Frontiers in Endocrinology·Samantha Alvarez-HerreraLenin Pavón
Jul 1, 2021·Neuropsychopharmacology Reports·Minami TasakiKazutaka Shimoda